A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

SUMMARY

N/A

COH Protocol Number : 15124

ClinicalTrials.gov Number : NCT02074839

Principal Investigator : Stein, Anthony M.D.

Sponsor : Agios Pharmaceuticals

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:2

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :